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Abstract
Introduction The phosphoinositide-3 kinase (PI3K)/Akt
pathway, operating downstream of epidermal growth factor
receptor (EGFR) and human epidermal growth factor receptor
(HER)2, is implicated in cell migration and survival. EGFR and
HER2 are expressed in circulating tumor cells, but the activation
status of downstream signaling molecules has not yet been
reported.
Methods To investigate expression levels of EGFR, HER2,
PI3K, and Akt in circulating tumor cells, we used peripheral
blood mononuclear cells from 32 cytokeratin-19 mRNA-positive
patients with early (n = 16) and metastatic (n = 16) breast
cancer.
Peripheral blood mononuclear cell cytospins were double
stained with cytokeratin antibody along with one of the
following: EGFR, phospho-EGFR, HER2, phospho-PI3K, or
phospho-Akt antibodies.
Results EGFR and HER2 were expressed in circulating tumor
cells of 38% and 50% patients with early and 44% and 63%
patients with metastatic disease, respectively. Interestingly,
phospho-PI3K and phospho-Akt expression levels were similar
at 88% (14 out of 16) and 81% (13 out of 16), respectively, in
circulating tumor cells of patients with early and metastatic
disease. Phospho-EGFR was observed in circulating tumor
cells of two (33%) early and six (86%) metastatic EGFR-positive
patients. Immunomagnetic separation of peripheral blood
mononuclear cells, using EpCAM antibody, and subsequent
double-staining experiments of circulating tumor cells showed
that EGFR was co-expressed with HER2, phospho-Akt and
phospho-PI3K kinases, indicating activation of the
corresponding survival signaling pathway.
Conclusions Our findings demonstrate that circulating tumor
cells express receptors and activated signaling kinases of the
EGFR/HER2/PI3K/Akt pathway, which could be used as
targets for their effective elimination.
Introduction
Circulating tumor cells (CTCs) have been identified in the
blood of patients bearing a wide range of malignancies [1,2],
but not in healthy individuals or in patients with nonmalignant
diseases [1]. CTCs have also been identified in significant pro-
portions of patients with both early and metastatic breast can-
cer, and their presence carries significant prognostic
information [3,4]. Indeed, the detection of CTCs before adju-
vant chemotherapy as well as the persistence of CTCs after
the completion of systemic adjuvant treatment is associated
with an unfavorable clinical outcome [4-6]. Similarly, in
patients with metastatic disease, elevated CTC numbers
before or soon after the initiation of chemotherapy is an indica-
tor of poor prognosis [7,8].
The malignant nature of CTCs is supported by the presence of
chromosomal alterations [9-12]. However, it appears that only
a small proportion of CTCs are capable of forming overt tumor
deposits [13]. The molecular characteristics of these cells may
play an important role in their survival and could therefore be
used to guide effective treatment strategies.
CK: cytokeratin; CTC: circulating tumor cell; EGFR: epidermal growth factor receptor; FISH: fluorescence in situ hybridization; HER: human epider-
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Epidermal growth factor receptor (EGFR; human epidermal
growth factor receptor [HER]1) is a member of the ErbB family
of receptors that also includes HER2, HER3, and HER4.
EGFR ligand binding induces the formation of homodimers
and heterodimers [14,15] and triggers the activation of down-
stream signaling pathways, such as the phosphoinositide-3
kinase (PI3K)/Akt pathway (among others), which control cell
proliferation, survival, and migration [16]. HER2 is the pre-
ferred partner for heterodimerization with the other members
of ErbB family of receptors [17], and its over-expression has
been reported to amplify EGFR signaling [18]. EGFR and lig-
ands such as transforming growth factor-α and amphiregulin
are over-expressed in a large subset of primary breast carcino-
mas [19,20]. Co-expression of these factors in breast cancer
confers poor prognosis and resistance to hormonal therapy
[21]. Moreover, inappropriate activation [22] or over-expres-
sion [23] of EGFR was associated with poor patient outcome.
Recent studies have reported expression of growth factor
receptors on CTCs of patients with breast and prostate can-
cer [15,24-26]. However, little is known about the presence of
activated receptors and downstream signaling kinases that
regulate pro-survival pathways in the CTCs of breast cancer
patients. The objective of this study was to investigate whether
EGFR and phosphorylated EGFR are expressed on CTCs iso-
lated from the blood of patients with breast cancer. The
expression of HER2 and the activation status of PI3K and Akt
kinases operating downstream of EGFR were also evaluated
in adjuvant as well as in metastatic settings.
Materials and methods
Patient samples and cytospin preparation
A total of 38 patients with detectable cytokeratin (CK)-19
mRNA positive cells [27,28] in peripheral blood were
screened using immunofluorescence, and 32 (84.2%) of them
with early (n = 16) and metastatic (n = 16) breast cancer who
were found to harbor occult tumor cells were enrolled in the
study. In addition 20 female normal blood donors were
included in the study as negative control individuals. Specifi-
cally, peripheral blood (10 ml in EDTA) was obtained before
the initiation of adjuvant treatment (usually 3 to 4 weeks after
primary surgery) or first-line chemotherapy for metastatic dis-
ease. All blood samples were obtained at the middle of vein
puncture after the first 5 ml of blood was discarded. These
precautions was undertaken in order to avoid contamination of
the blood sample with epithelial cells from the skin during sam-
ple collection. All patients gave their informed consent to par-
ticipate in the study, which has been approved by the Ethics
and Scientific Committees of our institution.
Peripheral blood mononuclear cells (PBMCs) were isolated
with Ficoll-Hypaque density gradient (d = 1,077 g/mol) centrif-
ugation at 1,800 rpm for 30 minutes. The PBMCs were
washed three times with phosphate-buffered saline and cen-
trifuged at 1,500 rpm for 10 minutes. Aliquots of 250,000
cells were centrifuged at 2,000 rpm for 2 minutes on glass
slides. Cytospins were dried up and stored at -80°C. Four to
five slides from each patient were used for staining
experiments.
Cell cultures
For control experiments we used two different breast cancer
cell lines, namely MCF7 and SKBR3, which express EGFR,
HER2, and the other examined signaling molecules. The
SKBR3 breast cancer cell line, which expresses high levels of
HER2 and EGFR, was used as a positive control for these mol-
ecules, and the MCF7 cell line as a positive control for phos-
phorylated Akt (pAkt) and phosphorylated PI3K (pPI3K) [29-
32]. The MCF7 mammary adenocarcinoma cells (obtained
from the American Type Culture Collection, Manassas, VA,
USA) were cultured in (vol:vol) 1:1 Dulbecco's modified Eagle
medium/Ham's F12 medium (GIBCO-BRL NY, USA), supple-
mented with 10% fetal bovine serum (GIBCO-BRL NY, USA),
2 mmol/l L-glutamine (GIBCO-BRL NY, USA.), 30 mmol/l
NaHCO3, 16 ng/ml insulin, and 50 mg/ml penicilline/strepto-
mycin (GIBCO-BRL NY, USA). SKBR3 cells were cultured in
McCoy's (GIBCO-BRL Co.), enriched with 10% fetal bovine
serum and 2 mmol/l L-glutamine supplemented with 50 mg/ml
penicilline/streptomycin.
Cells were maintained in a humidified atmosphere of 5% CO2/
95% air. Subcultivation for all cell lines was performed with
0.25% trypsin and 5 mmol/l EDTA (GIBCO-BRL Co.). All of
the experiments were performed during the logarithmic growth
phase. At 15 to 20 hours before the experiments, cells were
transferred in serum-starved medium containing only L-
glutamine, NaHCO3, and penicillin/streptomycin.
Confocal laser scanning microscopy
The presence of CK-positive cells in PBMCs of cytospin prep-
arations was investigated using two different antibodies,
according to the origin of the examined second antibody: the
mouse A45-B/B3 (detecting CK8, CK18, and CK19;
Micromet, Munich, Germany) for the rabbit anti-EGFR, anti-
pEGFR and anti-pAKT, and for the goat anti-pPI3K; and the
rabbit anti-pancytokeratin (Santa Cruz, Santa Cruz, CA, USA)
for the mouse anti-HER2. The pancytokeratin and HER2 anti-
bodies were validated and their specificity was confirmed in
normal donors and in CK-negative patients, as previously
reported [26]. Cytospins were also double stained with anti-
CD45 (common leukocyte antigen; Santa Cruz, Santa Cruz,
CA, USA) and A45-B/B3 antibodies in order to exclude pos-
sible ectopic expression of cytokeratins on hematopoietic
cells. The cytomorphological criteria proposed by Meng and
coworkers [33] (high nuclear/cytoplasmic ratio, larger cells
than white blood cells, and so on) were used to characterize a
CK-positive cell as a CTC.
Cytospins from the same patients were also stained for EGFR
(Santa Cruz, Santa Cruz, CA, USA), pEGFR (Invitrogen,Available online http://breast-cancer-research.com/content/10/5/R80
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Carlsbad, CA, USA), HER2 (Oncogene, Dermstadt, Ger-
many), pPI3K (Santa Cruz), and pAkt (Cell Signaling, Boston,
MA, USA) expressions in double-staining experiments and
assessed using confocal laser scanning microscopy [26].
Specific staining can be easily distinguished by double
immunofluorescence because of the differential intracellular
distribution of the examined molecules compared with non-
specific staining, as reported to Fehm and coworkers [34].
PBMC cytospins were fixed with cold aceton:methanol 9:1 for
20 minutes and stained for cytokeratin with a pancytokeratin
antibody, as mentioned above. Subsequently, the same slide
was stained with either EGFR, pEGFR, HER2, pPI3K, or pAkt
antibodies for 45 minutes. Cells were then incubated with the
corresponding secondary antibodies for 45 minutes. Slides
were analyzed using a confocal laser scanning microscope
module (Leica Lasertechnik, Heidelberg, Germany) and
images were analyzed using the respective software.
Immunomagnetic separation of CTCs
A total of 2 × 107 PBMCs, isolated as described above, were
placed in 1 ml phosphate-buffered saline/20% fetal calf
serum. Fifty microliters of CELLection beads (Dynal, Inc., Wir-
ral, UK; coated with EpCAM monoclonal antibody via a DNA
linker to provide a cleavable site for cell detachment) were
added to the PBMCs. After 30 minutes of incubation at 4°C,
cells were washed three times with RPMI/1% fetal calf serum.
Supernatant was removed and 4 μl of releasing buffer in 200
μl RPMI/1% fetal calf serum was added to the beads. After 15
minutes of incubation at room temperature, samples were
placed in a magnetic device and the released cells were trans-
ferred to a different tube. Isolated cells were centrifuged at
2,000 rpm for 2 minutes on glass slides. Double staining
microscopy experiments were performed as described
previously.
Results
Detection of circulating EGFR/CK double-positive tumor 
cells
EGFR-positive CTCs were observed in 38% (six out of 16)
and 44% (seven out of 16) patients with early and metastatic
breast cancer, respectively (Figure 1; see also Additional file
1). Patient characteristics are presented in Tables 1 and 2.
Table 3 presents the frequency of EGFR-positive cells
detected per sample. Among a total of 62 CTCs identified in
patients with early disease, seven (12%) stained positively for
both EGFR and CK, whereas the respective numbers for
patients with metastatic disease were 68 (42%) out of 161
cells.
The distribution of EGFR (red staining) and CK (green stain-
ing) in CTCs using immunofluorescence microscopy is dem-
onstrated in Figures 1a,b. Sequential sections of the CTCs
with confocal laser scanning microscopy confirmed that
EGFR staining was mainly membranous and – to a lesser
extent – intracellular, whereas CK was mainly located within
the cytoplasm (Figure 1a).
As a negative control, PBMCs from 20 healthy female blood
donors were also examined for EGFR/CK expression by dou-
Table 1
Patient characteristics: early disease
Characteristic n (%)
Menopausal status
Premenopausal 4 (25)
Postmenopausal 12 (75)
Unknown 0 (0)
Tumor size
pT1 3 (19)
pT2 10 (62)
pT3 3 (19)
Lymph node status
Node-negative 6(38)
Node-positive 10 (62)
Histologic grade
Grade 1 1 (6)
Grade 2 11 (69)
Grade 3 4 (25)
ER/PR tumor status
Positive 11 (69)
Negative 4 (25)
Unknown 1 (6)
HER2 tumor status
Positivea 3 (19)
Negative 12 (75)
Unknown 1 (6)
EGFR tumor status
Positive 3 (19)
Negative 9 (56)
Unknown 4 (25)
aA score +3 or fluorescence in situ hybridization positive. EGFR, 
epidermal growth factor receptor; ER, estrogen receptor; HER, 
human epidermal growth factor receptor; PR, progesterone receptor.Breast Cancer Research    Vol 10 No 5    Kallergi et al.
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ble staining experiments. There were no cells that could be
stained positive for both EGFR and CK in these samples.
However, in two samples, EGFR-positive and CK-negative
cells were detected. In order to characterize these cells fur-
ther, double-staining experiments with EGFR and CD45 anti-
bodies were conducted, which revealed positive staining for
both proteins, implying a hematopoietic origin for these cells
(data not shown).
The EGFR status of primary tumors and CTCs in early and
metastatic breast cancer patients is shown in Table 4. In three
out of 12 (25%) and four out of 10 (40%) there was a discrep-
ancy in EGFR expression between the primary tumor and
CTCs in early and metastatic breast cancer, respectively.
Detection of circulating HER2/CK double-positive tumor 
cells
To investigate HER2 expression in CTCs of the same cohort
of patients, double-staining experiments were performed using
HER2 and CK antibodies. The specificity of these antibodies
has been previously reported [26] and no CK-positive/HER2-
positive cells could be detected in normal blood donors or in
CK-19 mRNA-negative patients with early breast cancer.
HER2/CK double-positive cells were identified in CTCs of
eight out of 16 patients (50%) with early, and in CTCs from ten
out of 16 patients (63%) with metastatic disease (Figure 1c;
also see Additional file 1). The frequency of HER2-positive
cells detected per sample is presented in Table 3. The intrac-
ellular distribution of HER2 using confocal laser scanning
microscopy is shown in Figure 1c. Among a total of 51 CTCs
identified in patients with early disease, 19 (37%) were CK/
HER2-positive, whereas the respective numbers for patients
with metastatic disease were 35 out of 103 cells (34%). Three
(19%) patients with early and five (31%) patients with meta-
static breast cancer had CTCs in their blood expressing both
receptors (EGFR and HER2).
As shown in Table 4, there was a discrepancy between the
expression of HER2 in primary tumors and CTCs in seven out
of 15 (47%) and seven out of 16 (44%) patients with early and
metastatic breast cancer, respectively, implying that this is a
relatively common phenomenon.
Evaluation of EGFR and downstream PI-3 and Akt 
kinases activation in CTCs
To investigate whether EGFR is activated in CTCs, double-
staining experiments using pEGFR and A45-B/B3 pancytok-
eratin antibodies were performed. Indeed, pEGFR was
observed in patients with EGFR-positive CTCs. The propor-
tion of pEGFR expression in early and metastatic patients was
two out of six (33%) and six out of seven (86%), respectively
(Figure 2a). Among a total of 20 pEGFR-positive CTCs identi-
fied in patients with early disease, three (15%) stained positive
for both pEGFR and CK, whereas the respective numbers for
patients with metastatic disease were 22 out of 56 cells
(39%).
To evaluate whether pro-survival PI3K and Akt signaling
kinases operating downstream of EGFR are activated in
CTCs, double-staining experiments using CK and pPI3K or
Table 2
Patient characteristics: metastatic disease
Characteristic n (%)
Menopausal status
Premenopausal 5 (31)
Postmenopausal 9 (56)
Unknown 2 (13)
Disease sites
11  ( 6 )
27  ( 4 4 )
36  ( 3 8 )
≥ 42  ( 1 2 )
Predominantly visceral disease
Yes 3 (19)
No 13 (81)
Line of treatment
03  ( 1 9 )
16  ( 3 7 )
23  ( 1 9 )
≥- 3 4 (25)
ER/PR tumor status
Positive 11 (69)
Negative 5 (31)
HER2 tumor status
Positivea 5 (31)
Negative 11(69)
EGFR tumor status
Positive 1(6)
Negative 9 (56)
Unknown 6 (38)
aA score +3 or fluorescence in situ hybridization positive. EGFR, 
epidermal growth factor receptor; ER, estrogen receptor; HER, 
human epidermal growth factor receptor; PR, progesterone receptor.Available online http://breast-cancer-research.com/content/10/5/R80
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pAkt antibodies were performed [16]. It was observed that the
great proportion of patients (88%) with both early and meta-
static disease harbored CTCs expressing pPI3K (Figure 2b;
also see Additional file 1). The frequency of pPI3K-positive
CTCs is shown in Table 3. Interestingly, a large proportion of
CTCs of each individual patient were pPI3K positive both in
the early (median 100%, range 80% to 100%) and the meta-
static (median 90%, range 12.50% to 100%) settings.
Similarly, double-staining experiments using CK and pAkt anti-
bodies revealed the presence of pAkt (Figure 2c) in 13 out of
16 patients (81%) both in early and metastatic breast cancer
(see Additional file 1). Moreover, a significant proportion of
CTCs of each patient were pAkt positive both in early (median
100%, range 16.6% to 100%) and metastatic (median 83%,
range 8.70% to 100%) settings. The frequency of pAkt-posi-
tive CTCs is presented in Table 3. Double-staining experi-
ments using blood from 10 normal female donors with A45-B/
B3 antibody coupled with either pPI3K or pAkt revealed no
double-stained cells, implying the absence of CK-positive
cells, which express activated signaling kinases in the blood of
healthy women.
Co-expression of EGFR and activated kinases in CTCs
To investigate further whether EGFR and HER2 as well as
activated PI3K and Akt signaling kinases are co-expressed in
CTCs, we performed immunomagnetic separation of CTCs
using EpCAM coated beads in three patients whose CTCs
were positive for all of the examined molecules. Subsequently,
cytospins of the isolated cells were double stained with EGFR
and either HER2, pEGFR, pPI3K, or pAkt. As shown in Figure
3, both EGFR and HER2 were co localized on the same cell.
Moreover, EGFR was shown to be co-expressed with pEGFR,
pPI3K, or pAkt (Figure 3a), implying the presence of an acti-
vated pathway in CTCs downstream of EGFR involving PI3K
and Akt.
Discussion
The presence of CTCs in the peripheral blood of patients with
breast cancer correlates with poor clinical outcome [4-7]. In
recent years, significant effort has been made to achieve spe-
cific and sensitive detection of CTCs, which poses significant
technical challenges because of the rarity of these cells
among an abundance of erythrocytes and leukocytes
[9,35,36]. The rarity of CTCs is also a significant limiting factor
for their detailed characterization. It is well known that breast
cancers exhibit significant heterogeneity and – at least theo-
retically – the population of CTCs should include the fraction
of tumor cells with the biological potential to form metastatic
deposits. Therefore, the genomic and phenotypic analysis of
CTCs is of paramount importance for patients with breast can-
cer, because it provides an insight into the metastatic proper-
ties of the primary tumor and permits the exploitation of
targeted therapies that are more likely to be effective. A CK-
positive cell can be characterized as a CTC if cytomorpholog-
ical criteria described by Meng and coworkers [33] are satis-
fied. Furthermore, we and others have previously
demonstrated the malignant origin of CK-positive cells,
because fluorescence in situ hybridization (FISH) analysis
identified HER2 gene amplification and aneusomy [10,12].
EGFR is frequently over-expressed in breast cancers [19,20],
and EGFR signaling is correlated with poor patient outcome
[22,23]. In the present study, by using immunofluorescence
microscopy, we detected EGFR-positive CTCs in 38% and
44% of patients with early and metastatic disease, respec-
tively, harboring CTCs in their blood. In accordance with these
findings, EGFR mRNA expression has previously been
reported in the blood of 22% to 48% of patients with meta-
static breast cancer [37,38]. However, it should be noted that
molecular techniques suffer from a relative lack of specificity,
because illegitimate transcription of the EGFR gene in leuko-
cytes cannot be excluded [39]. Conversely, cytological tech-
Table 3
Number of EGFR, HER2, pPI3K, and pAkt-positive CTCs in breast cancer patients
Number of 
CTCs per 
sample
EGFR HER2 pPI3K PAkt
Early disease 
(n = 16)
Metastatic 
disease (n = 16)
Early disease 
(n = 16)
Metastatic 
disease (n = 
16)
Early disease 
(n = 16)
Metastatic 
disease (n = 
16)
Early disease 
(n = 16)
Metastatic 
disease (n = 
16)
1 2 (13) 1 (6) 5 (31) 6 (38) 6 (31) 3 (19) 5 (31) 4 (25)
2 4 (25) 1 (6) 1 (6) 2 (13) 5 (31) 2 (13) 4 (25) 3 (19)
3 -- ---4  ( 2 5 ) 1  ( 6 ) 2  ( 1 3 )
4 - 2 (13) 1 (6) 1 (6) 2 (13) 2 (13) -
≥ 5 - 3 (19) 1 (6) 1 (6) 1 (6) 5 (31) 1 (6) 4 (25)
Values are expressed as number (%). CTC, circulating tumor cell; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor 
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niques permit evaluation of cell morphology and identification
of those cells that have tumor-like appearance. In accordance
with this assumption, in the present study we identified EGFR
expressing hematopoetic cells in 10% of samples from healthy
donors.
Despite the relatively small number of patients for whom the
primary tumor was available for EGFR evaluation, it was evi-
dent that an EGFR-negative primary tumor does not preclude
the presence of EGFR-expressing CTCs. Moreover, a higher
proportion of the evaluated CTCs was stained positive for
EGFR in patients with metastatic than in patients with early
breast cancer. This observation suggests that EGFR is
expressed in a predominant clone of cells that contribute to
disease progression. Conversely, HER2 expression in the total
number of CTCs in early and metastatic disease was similar.
This could probably be explained by the observation that
human breast cancer is often characterized by a gradual pro-
gression to an estrogen-independent, EGFR-positive, and
highly metastatic phenotype [40].
In a previous report [26], HER2 expression was reported in
cells circulating in the blood of patients with early breast can-
cer. In another study [15], the presence of HER2-expressing
CTCs was found to be suggestive of poor disease-free and
overall survival in stage I to III breast cancer. HER2/CK-posi-
tive cells were recently characterized as tumor cells using
FISH analysis [11]. In the present study, double-staining
Figure 1
EGFR and HER2 expression in CTCs from breast cancer patients EGFR and HER2 expression in CTCs from breast cancer patients. (a) Representative images of confocal laser scanning microscopic sections of 
PBMC cytospins stained with pancytokeratins A45 B/B3 (green) and EGFR anti-rabbit (red) antibodies, showing consecutive scanning sections 
from the upper cytoplasmic region toward the basal attachment site in step sizes of 0.8 μm (magnification: 600×). (b) Representative images of a 
cytospin, double stained with monoclonal pancytokeratin (A45-B/B3; green) and polyclonal EGFR anti-rabbit (red) antibodies (magnification: 600×). 
Also shown is quantification of EGFR and CK co-expression in adjuvant and metastatic CTCs. (c) Representative image of cytospin, double stained 
with polyclonal pancytokeratin and monoclonal HER2 (green) antibodies (magnification: 600×). Quantification of HER2 and CK co-expression in 
adjuvant and metastatic CTCs. CK, cytokeratin; CTC, circulating tumor cell; EGFR, epidermal growth factor receptor; HER, human epidermal growth 
factor receptor; PBMC, peripheral blood mononuclear cell.Available online http://breast-cancer-research.com/content/10/5/R80
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experiments using pancytokeratin and HER2 antibodies
revealed that CK-positive CTCs also co-express HER2. The
50% expression rate in patients with early disease shown here
is almost identical to the 48.6% of HER2-positive CTCs in
patients with primary breast cancer reported recently by Wulf-
ing and coworkers [15]. It is interesting to note that, in accord-
ance with the above mentioned study [15], we observed a
discrepancy between the detection of HER2-positive CTCs
and the HER2 staining score of the corresponding primary
tumor (Table 4). HER2 positivity in the primary tumor was
assessed in accordance with the 2007 criteria proposed by
Wolff and coworkers [41], and FISH evaluation was per-
formed in patients with immunohistochemical staining score 2.
This discrepancy was also observed in the EGFR expression
pattern (Table 4). This could be related to the different meth-
ods used for the evaluation of these receptors in the primary
tumors and/or the heterogeneity of CTCs. Interestingly, by
using immunomagnetic separation of CTCs in three patients,
co-localization of both receptors on same cells was demon-
strated, thus suggesting that an EGFR and HER2 crosstalk
may be operating [42].
Additional experiments revealed that pEGFR is also expressed
on the CTCs of both early and metastatic breast cancer
patients. The presence of pEGFR on CTCs further supports
the hypothesis that EGFR plays a functional role in the biology
of these cells. Indeed, EGFR activation was demonstrated in a
higher proportion of patients with metastatic disease com-
pared with patients with early disease. Moreover, a higher pro-
portion of the total number of EGFR-expressing CTCs was
activated in advanced compared with early disease. Although
the small number of patients examined precludes firm conclu-
sions, this finding further suggests that EGFR signaling may
be involved in breast cancer progression.
PI3K and Akt kinases operate downstream of EGFR and
HER2 in cancer cells, transmitting signals that regulate cell
survival and cell migration [16,43-45]. In a previous report
[26], pPI3K was shown to be expressed on the CTCs of
Table 4
EGFR and HER2 expression in primary tumor and in CTCs
Early disease Metastatic disease
Primary tumor CTCs Primary tumor CTCs
Patient number HER2 EGFR HER2 EGFR HER2 EGFR HER2 EGFR
1 - +++- - +-
2+ a NA + - + - + -
3- - - + + N A + +
4 --+ -----
5 --+ ---+ -
6- N A + + - N A - -
7 - +- ++- +-
8 ------+ -
9 + ----N A --
1 0 +- +++- ++
11 - + - - + NA - +
1 2 --+ --+ --
1 3 --+ --N A -+
1 4 ------+ +
15 - NA - - - NA + +
16 NA NA - + - - + +
aScore +3 or fluorescence in situ hybridization positive. CTC, circulating tumor cell; EGFR, epidermal growth factor receptor; HER, human 
epidermal growth factor receptor.Breast Cancer Research    Vol 10 No 5    Kallergi et al.
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patients with early breast cancer. Here we report that pPI3K
and pAkt were identified in a significant proportion of CTCs
from patients with early and metastatic disease. Their co-local-
ization with EGFR is suggestive of an active pathway involving
PI3K and Akt that is initiated upon EGFR activation. Moreover,
a statistically significant correlation (P = 0.038) between the
number of CTCs expressing pPI3K and pAkt in metastatic
patients was observed, suggesting the existence of an active
pathway in these cells; conversely, the same correlation was
not observed in patients with early breast cancer. This could
be due to the heterogeneity of CTCs in these patients [13].
Because the aim of the present study was to evaluate the
expression of EGFR, HER2, pAkt and pPI3K in CTCs, the pre-
sented data do not have the statistical power to establish clin-
ical correlations because of the small number of enrolled
patients. The clinical significance of EGFR, HER2, pAkt, and
pPI3K expression in CTCs should be investigated in large pro-
spective clinical trials.
Conclusion
This is the first report to demonstrate expression of activated
EGFR and Akt in CTCs in both adjuvant and metastatic set-
tings. The co-expression of HER2 receptor could confer a
more aggressive phenotype on EGFR-positive CTCs [46,47].
Our observations suggest that EGFR-triggered and/or HER2-
triggered PI3K/Akt activation may be involved in the regulation
of the malignant and metastatic potential of CTCs. Therefore,
these molecules could serve as targets for the elimination of
Figure 2
EGFR, PI3K, and Akt activation in CTCs from breast cancer patients EGFR, PI3K, and Akt activation in CTCs from breast cancer patients. (a) Representative micrograph of cytospin, double-stained with monoclonal 
pancytokeratin (A45-B/B3; green) and polyclonal pEGFR anti-rabbit (red) antibodies (magnification: 600×). Also shown is quantification of pEGFR 
and CK co-expression in adjuvant and metastatic CTCs. (b) Representative image of a cytospin, double stained with monoclonal pancytokeratin 
(A45-B/B3; green) and polyclonal pPI3K (red) antibodies (magnification: 400×). Also shown is quantification of pPI3K and CK co-expression in 
adjuvant and metastatic CTCs. (c) Representative micrograph of cytospin, double stained with monoclonal pancytokeratin (A45-B/B3; green) and 
polyclonal pAkt (red) antibodies (magnification: 600 ×). Also shown is quantification of pAkt and CK co-expression in adjuvant and metastatic CTCs. 
CK, cytokeratin; CTC, circulating tumor cell; EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; PI3K, phosph-
oinositide-3 kinase.Available online http://breast-cancer-research.com/content/10/5/R80
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micrometastatic disease. In view of the limited capacity of
standard systemic treatments to control or eliminate CTCs
[48], the data presented in the present study could have
important therapeutic implications for novel targeted treatment
strategies against micrometastatic disease.
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